

PRESS RELEASE

Stockholm, 13 September, 2013



The Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program

The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 26 April 2013 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive program resolved by the annual general meeting – on a directed share issue of no more than 754,912 redeemable and convertible class C shares.

The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on one or several occasions until the annual general meeting in 2014 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 19 September – 29 September 2013.

The company currently holds 4,408,260 own class C shares. Subsequently to the effected repurchase of class C shares above, the number of own class C shares will amount to 5,163,172.

The class C shares will, following the repurchase, be converted to common shares in the number that is required to ensure delivery under the incentive program.

PRESS RELEASE

Stockholm, 13 September, 2013



About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com

For more information – not for publication

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +46 8 697 20 00

jorgen.winroth@sobi.com

The information was released for public distribution on 13 September 2013 at 08:00 CET.

Swedish Orphan Biovitrum AB

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 697 20 00 Fax +46 697 20 00 www.sobi.com